3 things to know about Novavax, the new vaccine soon available in France


AND FIVE- The first injections in France of the anti-Covid vaccine from the American Novavax could take place “at the beginning of February”, according to the Ministry of Health. Based on a more traditional technology than RNA, it received the green light from the HAS on Friday.

“It’s a welcome addition to the arsenal to protect Europeans”, welcomed the President of the European Commission Ursula Von der Leyen in December, announcing the authorization of the anti-Covid vaccine from Novavax in the EU, with an anticipated contract with the American laboratory for 200 million doses. The Nuvaxovid vaccine, which received the green light from the Haute Autorité de Santé (HAS) on Friday, could be offered in France from the beginning of February, the Ministry of Health announced earlier. Based on a more traditional technology than messenger RNA vaccines, it could reduce the skepticism of some of the unvaccinated.

All the info on

Covid-19: the challenge of vaccination

What is a “subunit” vaccine?

Neither viral vector vaccine (like those from AstraZeneca or Johnson & Johnson) nor messenger RNA (like Pfizer or Moderna), Nuvaxovid uses yet another technology: it is a “subunit” vaccine, also called “recombinant protein “. The principle is to inject into the body a protein which resembles the now famous “Spike protein” of the virus, to trigger the production of antibodies against the real S protein of the Coronavirus.

The process is already known, and used for example in vaccines against whooping cough or hepatitis-B. It is also this same technology that uses the vaccine that the French laboratory Sanofi is developing, and which could arrive on the market in 2022, after two postponements.

Easier to store and transport

A definite advantage of the Novavax subunit vaccine: it can be stored between 2° and 8° Celsius, which will facilitate its transport and distribution. Messenger RNA vaccines require extremely low temperatures, which require freezers that most low-income countries do not have, on a large scale at least, – even if Pfizer recently relaxed the storage conditions for its vaccine. By arriving on the market late, the doses of Novavax are all the more likely to be in excess in developed countries, and could then be redistributed via the Covax system.

How effective against variants?

Last June, Novavax laboratories published the first conclusions of their phase 3 clinical trials, conducted with 30,000 people. On this basis, the firm assured that its vaccine protected “100% against moderate and severe forms” of the disease, and 90.4% overall”. But even more, Novavax announced an effectiveness of 93% against the “predominant variants”, even if at the date of this study, neither the Delta variant nor the Omicron were still part of it.

The World Health Organization urgently approved this vaccine from the firm Novavax in December, indicating that it was the tenth thus validated. The WHO recommends the vaccine for anyone over the age of 18, respecting an interval of at least three weeks between two doses.

On the same subject

The most read articles

Tsunami warning from Japan to US: Threat over but heavy damage in Tonga

LIVE – Vaccine pass: the text voted in the Senate, towards final adoption this Sunday

Presidential 2022: here are the seven left-wing candidates for the popular Primary

In Rome, the most expensive villa in the world put up for sale

EXCLUSIVE – Presidential 2022: discover the results of our daily survey of January 14

LCI-Logo
defends the ambition of information
free,
verified and accessible to all thanks to the income of the
advertising .

To help us keep this service free you can “change your choice” and accept all cookies.





Source link -81